Katja Schulze

TL;DR: Dual HER2-targeted therapy with pertuzumab plus trastuzumAB is well tolerated and could represent a therapeutic opportunity for patients with heavily pretreated, Her2-amplified metastatic colorectal cancer.

TL;DR: The MyPathway trial as discussed by the authors evaluated the activity of US Food and Drug Administration-approved therapies in non-indicated tumours with potentially actionable molecular alterations, including HER2 amplification, overexpression, or both treated with a dual anti-HER2 regimen.

TL;DR: A large multicentre trial has shown that preoperative immune checkpoint inhibitor therapy may be of benefit in early-stage NSCLC and aims to extend the scope of this study to include further studies in patients with recurrent NSCLCs.

TL;DR: In this article, the authors investigated oncogene-specific differences in these markers and clinical outcome and found that high TMB and PD-L1 expression are predictive for benefit from immune checkpoint blockade (ICB) treatment in non-small cell lung cancer.

TL;DR: It is suggested that matched targeted therapy for SGC has promising efficacy, supporting molecular profiling in treatment determination and the clinical benefit rate was 67% and the median progression-free survival was 8.6 months.